Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LOX | P28300 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13056784 | 0.82 | KDM4E (0.33) | KDM4EGAATHRBRECQLL3MBTL1 | |
| SCHEMBL16001684 | 0.80 | KDM4E (0.32) | KDM4EGAATHRBRECQLL3MBTL1 | |
| SCHEMBL23952968 | 0.76 | KDM4E (0.30) | KDM4EGAATHRBRECQLL3MBTL1 | |
| SCHEMBL15912312 | 0.76 | KDM4E (0.30) | KDM4EGAATHRBRECQLL3MBTL1 | |
| SCHEMBL25161914 | 0.68 | KIF11 (0.44) | KDM4E | |
| SCHEMBL20087083 | 0.67 | KDM4E (0.36) | KDM4EGAATHRBRECQLL3MBTL1 | |
| SCHEMBL12091405 | 0.67 | — | — | |
| SCHEMBL20087098 | 0.63 | KDM4E (0.33) | KDM4EGAATHRBRECQLL3MBTL1 | |
| SCHEMBL10152389 | 0.60 | KDM4E (0.35) | KDM4EGAATHRBRECQLL3MBTL1 | |
| SCHEMBL18087055 | 0.58 | KDM4E (0.30) | KDM4EGAATHRBRECQLL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018134-A1 | 6-Substituted Pyridazine Compounds as SMARCA2 and/or SMARCA4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2024-01-18 | — | — | US | disclosed |
| US-20240018134-A1 | 6-Substituted Pyridazine Compounds as SMARCA2 and/or SMARCA4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2024-01-18 | — | — | US | disclosed |
| US-20230255950-A1 | 3-(Hydroxy)-Pyridin-4(1H)-One Compounds and Methods of Making and Using the Same | GEORGIA TECH RESEARCH CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-11654137-B2 | 3-(hydroxy)-pyridin-4(1H)-one compounds and methods of making and using the same | GEORGIA TECH RESEARCH CORPORATION (US) | 2023-05-23 | — | — | US | disclosed |
| US-20230144203-A1 | DRUG CONJUGATE OF ERIBULIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20180222882-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-22 | — | — | US | disclosed |
| US-9879028-B2 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170342040-A1 | NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-11-30 | — | — | US | disclosed |
| US-20170342040-A1 | NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-11-30 | — | — | US | disclosed |
| US-20120041190-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-16 | — | — | US | disclosed |
| US-20120014906-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-8044211-B2 | P38 MAP kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-10-25 | — | — | US | disclosed |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. | 2011-08-25 | — | — | US | disclosed |
| US-20110034520-A1 | Inhibitors of P38 Map Kinase | MACROPHAGE PHARMA LIMITED (GB) | 2011-02-10 | — | — | US | disclosed |
| US-20090203711-A1 | Inhibitors of P38 Map Kinase | CHROMA THERAPEUTICS LTD. (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203711-A1 | Inhibitors of P38 Map Kinase | CHROMA THERAPEUTICS LTD. (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2009-05-21 | — | — | US | disclosed |
| US-20090099185-A1 | P38 Map Kinase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11654137-B2 | 3-(hydroxy)-pyridin-4(1H)-one compounds and methods of making and using the same | KDM1B, KDM3A, KDM1A | KDM4E 10/4885GAA 3242/4885THRB 4035/4885 |
| US-20120041190-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | KDM4E 796/4885GAA 3302/4885THRB 2976/4885 |
| US-20170342040-A1 | NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS | RARA, RARB, RARG | KDM4E 1792/4885GAA 1733/4885THRB 1975/4885 |
| US-20230255950-A1 | 3-(Hydroxy)-Pyridin-4(1H)-One Compounds and Methods of Making and Using the Same | KDM1B, KDM3A, KDM1A | KDM4E 10/4885GAA 3242/4885THRB 4035/4885 |
| US-20090099185-A1 | P38 Map Kinase Inhibitors | MAPK1, CNKSR1, MAPK3 | KDM4E 4343/4885GAA 3102/4885THRB 571/4885 |
| US-20090203711-A1 | Inhibitors of P38 Map Kinase | MAPK1, MAPK3, CNKSR1 | KDM4E 3422/4885GAA 4045/4885THRB 996/4885 |
| US-20180222882-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | KDM4E 3081/4885GAA 4532/4885THRB 141/4885 |
| US-20120014906-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | KDM4E 683/4885GAA 556/4885THRB 3340/4885 |
| US-20240018134-A1 | 6-Substituted Pyridazine Compounds as SMARCA2 and/or SMARCA4 Degraders | SMARCC1, SMARCC2, SMARCA4 | KDM4E 363/4885GAA 1001/4885THRB 3221/4885 |
| US-20110034520-A1 | Inhibitors of P38 Map Kinase | MAPK3, MAPK1, MAPKAPK3 | KDM4E 2951/4885GAA 3189/4885THRB 1276/4885 |
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CDK1, AURKC, CSNK1G3 | KDM4E 1484/4885GAA 1657/4885THRB 2199/4885 |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, MAP3K19, MAP4K2 | KDM4E 1048/4885GAA 2645/4885THRB 1301/4885 |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | EGFR, ERBB2, BRCA1 | KDM4E 4347/4885GAA 611/4885THRB 403/4885 |
| US-20230144203-A1 | DRUG CONJUGATE OF ERIBULIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | ERLIN1, ERLIN2, EZR | KDM4E 3448/4885GAA 1578/4885THRB 3886/4885 |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | HRAS, VHL, ESRRB | KDM4E 3356/4885GAA 1702/4885THRB 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.